• 68k views

Medical management of GI Neuroendocrine tumor

The medical management of gastrointestinal neuroendocrine tumors (NETs) involves a tailored approach based on the tumor's grade, stage, and specific hormonal secretion patterns. Somatostatin analogs, such as octreotide and lanreotide, are commonly used to control symptoms related to hormone hypersecretion and to stabilize tumor growth. For well-differentiated NETs with advanced disease, targeted therapies like everolimus and sunitinib may be considered to inhibit mTOR and tyrosine kinase pathways, respectively. Peptide receptor radionuclide therapy (PRRT) with agents like lutetium-177 DOTATATE has shown efficacy in certain cases. Systemic chemotherapy, often with streptozocin-based regimens, may be employed for poorly differentiated or aggressive tumors. Close monitoring through imaging studies, biomarker assessments, and multidisciplinary collaboration between oncologists, endocrinologists, and surgeons is essential for an integrated and individualized approach to the medical management of GI neuroendocrine tumors. Additionally, patient education and support are crucial components to address the chronic nature of this condition and optimize the patient's overall well-being.

About the Speaker

Dr. Cherian Thampy Profile Image

Dr. Cherian Thampy

Consultant Medical Oncologist, NMC Specialty Hospital, AUH

Upcoming Case Discussions

Leave a Comment

Your email address will not be published.

Author Post

authorimage

Impact

+

Talks

+

webinar

+

no.of registrations

One liner about speaker

Why is speaker relevant?

Dr. Cherian Thampy's Talks on Assimilate

webinar
Dr. Cherian Thampy
  • 0

The medical management of gastrointestinal neuroendocrine tumors (NETs) involves a tailored approach based on the tumor's grade, stage, and specific hormonal secretion patterns. Somatostatin analogs, such as octreotide and lanreotide, are commonly used to control symptoms related to hormone hypersecretion and to stabilize tumor growth. For well-differentiated NETs with advanced disease, targeted therapies like everolimus and sunitinib may be considered to inhibit mTOR and tyrosine kinase pathways, respectively. Peptide receptor radionuclide therapy (PRRT) with agents like lutetium-177 DOTATATE has shown efficacy in certain cases. Systemic chemotherapy, often with streptozocin-based regimens, may be employed for poorly differentiated or aggressive tumors. Close monitoring through imaging studies, biomarker assessments, and multidisciplinary collaboration between oncologists, endocrinologists, and surgeons is essential for an integrated and individualized approach to the medical management of GI neuroendocrine tumors. Additionally, patient education and support are crucial components to address the chronic nature of this condition and optimize the patient's overall well-being.